S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.31 (+0.38%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.31 (+0.38%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.31 (+0.38%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.31 (+0.38%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
CVE:VIV

Avivagen (VIV) Stock Forecast, Price & News

C$0.01
0.00 (0.00%)
(As of 10:22 AM ET)
Compare
Today's Range
C$0.01
C$0.02
50-Day Range
C$0.01
C$0.05
52-Week Range
C$0.01
C$0.21
Volume
12,700 shs
Average Volume
69,200 shs
Market Capitalization
C$776,900.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

VIV stock logo

About Avivagen (CVE:VIV) Stock

Avivagen Inc., a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, and Malaysia. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.

Receive VIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avivagen and its competitors with MarketBeat's FREE daily newsletter.

VIV Stock News Headlines

Avivagen (CVE:VIV) Sets New 1-Year Low at $0.01
Avivagen (CVE:VIV) Hits New 52-Week Low at $0.01
Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
Avivagen Inc. (VIV.V)
Closing Bell: Avivagen Inc down on Thursday (VIV)
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Avivagen Announces AGM Results
Closing Bell: Avivagen Inc flat on Thursday (VIV)
Closing Bell: Avivagen Inc flat on Wednesday (VIV)
Avivagen (CVE:VIV) Hits New 52-Week Low at $0.05
Avivagen reports FY results
Avivagen Inc. (VIVXF)
Merry Christmas
Avivagen Earnings, Revenue Miss in Q3
Avivagen reports Q3 results
Stocks in play: Avivagen Inc
See More Headlines

VIV Price History

VIV Company Calendar

Last Earnings
3/16/2023
Today
6/01/2023
Next Earnings (Estimated)
6/21/2023

Industry, Sector and Symbol

Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
C$-5,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$403,780.00
Cash Flow
C$0.00 per share
Book Value
C($0.09) per share

Miscellaneous

Free Float
N/A
Market Cap
C$1.17 million
Optionable
Optionable
Beta
0.77

Key Executives

  • Mr. G. F. Kym Anthony (Age 67)
    CEO & Director
    Comp: $469.17k
  • Dr. Graham Burton Ph.D.
    Co-Founder, Chief Scientific Officer & Director
  • Dr. James Nickerson Ph.D.
    Pres and Exec. VP of Bus. Devel. & Product Innovation
  • Mr. Ira Levy
    Interim Chief Financial Officer
  • Mr. Drew Basek
    Director of Investor Relations
  • Ms. Tracy Gillett BVSC
    Director of Companion Animal & Marketing Mang.













VIV Stock - Frequently Asked Questions

How have VIV shares performed in 2023?

Avivagen's stock was trading at C$0.08 at the beginning of the year. Since then, VIV stock has decreased by 81.3% and is now trading at C$0.02.
View the best growth stocks for 2023 here
.

When is Avivagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 21st 2023.
View our VIV earnings forecast
.

How were Avivagen's earnings last quarter?

Avivagen Inc. (CVE:VIV) announced its quarterly earnings data on Thursday, March, 16th. The company reported ($0.01) EPS for the quarter. The firm earned $0.07 million during the quarter.

What other stocks do shareholders of Avivagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avivagen investors own include Astrotech (ASTC), Arcturus Therapeutics (ARCT), Aptose Biosciences (APTO), Appili Therapeutics (APLIF), Argan (AGX), Applied Genetic Technologies (AGTC), AES (AES) and AbbVie (ABBV).

What is Avivagen's stock symbol?

Avivagen trades on the Canadian Venture Exchange (CVE) under the ticker symbol "VIV."

How do I buy shares of Avivagen?

Shares of VIV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Avivagen's stock price today?

One share of VIV stock can currently be purchased for approximately C$0.02.

How much money does Avivagen make?

Avivagen (CVE:VIV) has a market capitalization of C$1.17 million and generates C$403,780.00 in revenue each year. The company earns C$-5,670,000.00 in net income (profit) each year or C($0.07) on an earnings per share basis.

How can I contact Avivagen?

Avivagen's mailing address is Av Engenheiro Luis Carlos Berrini, 1376 32 andar, Sao Paulo, Sao Paulo 04.571-936. The official website for the company is www.avivagen.com. The company can be reached via phone at 613-949-8164.

This page (CVE:VIV) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -